Imbeau Jacques
Dental Services, Bay of Plenty Environmental Health Clinic, New Zealand.
Cranio. 2005 Apr;23(2):100-12. doi: 10.1179/crn.2005.015.
Through-transmission alveolar ultrasonography (TAU) is a novel imaging modality in dental medicine. A brief introduction to through-transmission ultrasonography (TTU) is followed by a description of the first commercially available TAU device, the Cavitat CAV 4000 (Cavitat Medical Technologies, Inc., Alba, TX). Recent associations between systemic osteoporosis, oral osteoporosis, periodontal diseases, and cardiovascular diseases underline the importance of early detection and treatment of oral cancellous bone pathologies associated with low bone density (LBD), such as regional ischemic osteoporosis, chronic nonsuppurative osteomyelitis, bone marrow edema, and cavitational ischemic osteonecrosis (osteocavitation). While the impact of osteoporosis on maxillofacial bones is acknowledged, there is a lack of reliable prevalence rate, and the National Institutes of Health (NIH) recommend that more attention should be paid to skeletal health, especially in persons with conditions known to be associated with secondary osteoporosis. TAU, a safe and effective imaging modality, can be a valuable tool in research as well as for the clinical assessment of alveolar cancellous bone pathologies associated with LBD and ischemia.
穿透式肺泡超声检查（TAU）是牙科医学中的一种新型成像方式。在简要介绍穿透式超声检查（TTU）之后，将描述首款商用TAU设备——Cavitat CAV 4000（Cavitat Medical Technologies, Inc., Alba, TX）。全身骨质疏松症、口腔骨质疏松症、牙周疾病和心血管疾病之间最近的关联凸显了早期检测和治疗与低骨密度（LBD）相关的口腔松质骨病变（如局部缺血性骨质疏松症、慢性非化脓性骨髓炎、骨髓水肿和空洞性缺血性骨坏死（骨空洞症））的重要性。虽然骨质疏松症对颌面部骨骼的影响已得到认可，但缺乏可靠的患病率数据，美国国立卫生研究院（NIH）建议应更加关注骨骼健康，尤其是对已知与继发性骨质疏松症相关疾病的患者。TAU作为一种安全有效的成像方式，在研究以及对与LBD和缺血相关的肺泡松质骨病变进行临床评估方面可能是一种有价值的工具。
